Medicine-induced Cardiac Hemodialysis on COVID-19 | Clinical Trial | StuddyBuddy@endsection Medicine-induced Cardiac Hemodialysis on COVID-19
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05711810

Medicine-induced Cardiac Hemodialysis on COVID-19

Conditions: Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis, Vaccines, Myocarditis Allergic, Infection Viral

Sex: All
Phase: PHASE4
Enrollment: 1
Sponsor: Yang I. Pachankis

Location: China

Summary

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

Eligibility Criteria

Inclusion Criteria:No mRNA vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. It is theorized that the more advanced the vaccine production technology, the deeper the poisoning.Exclusion Criteria:healthy individuals with no myocarditis or unvaccinated without infection by SARS-CoV seriespersons with diabetes (Paxlovid and PrEP treatments can be applied according to availability)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05711810). StuddyBuddy aggregates publicly available trial information.